These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 26276523)
1. Association between variants in inflammation and cancer-associated genes and risk and survival of cholangiocarcinoma. Chaiteerakij R; Juran BD; Aboelsoud MM; Harmsen WS; Moser CD; Giama NH; Allotey LK; Mettler TA; Baichoo E; Zhang X; Therneau TM; Lazaridis KN; Roberts LR Cancer Med; 2015 Oct; 4(10):1599-602. PubMed ID: 26276523 [TBL] [Abstract][Full Text] [Related]
2. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Melum E; Karlsen TH; Schrumpf E; Bergquist A; Thorsby E; Boberg KM; Lie BA Hepatology; 2008 Jan; 47(1):90-6. PubMed ID: 18023027 [TBL] [Abstract][Full Text] [Related]
3. Elevated expression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 in primary sclerosing cholangitis: ιmplications for cholangiocarcinogenesis. Ishii Y; Sasaki T; Serikawa M; Minami T; Okazaki A; Yukutake M; Ishigaki T; Kosaka K; Mouri T; Yoshimi S; Shimizu A; Tsuboi T; Chayama K Int J Oncol; 2013 Oct; 43(4):1073-9. PubMed ID: 23900502 [TBL] [Abstract][Full Text] [Related]
4. Risk factors for cholangiocarcinoma in high-risk area of Thailand: role of lifestyle, diet and methylenetetrahydrofolate reductase polymorphisms. Songserm N; Promthet S; Sithithaworn P; Pientong C; Ekalaksananan T; Chopjitt P; Parkin DM Cancer Epidemiol; 2012 Apr; 36(2):e89-94. PubMed ID: 22189445 [TBL] [Abstract][Full Text] [Related]
5. Association of NRF2 polymorphism with cholangiocarcinoma prognosis in Thai patients. Khunluck T; Kukongviriyapan V; Puapairoj A; Khuntikeo N; Senggunprai L; Zeekpudsa P; Prawan A Asian Pac J Cancer Prev; 2014; 15(1):299-304. PubMed ID: 24528044 [TBL] [Abstract][Full Text] [Related]
6. Prognostic assessment of three single-nucleotide polymorphisms (GNB3 825C>T, BCL2-938C>A, MCL1-386C>G) in extrahepatic cholangiocarcinoma. Fingas CD; Katsounas A; Kahraman A; Siffert W; Jochum C; Gerken G; Nückel H; Canbay A Cancer Invest; 2010 Jun; 28(5):472-8. PubMed ID: 19968497 [TBL] [Abstract][Full Text] [Related]
7. A common variant in the precursor miR-146a sequence does not predispose to cholangiocarcinoma in a large European cohort. Mihalache F; Hoblinger A; Acalovschi M; Sauerbruch T; Lammert F; Zimmer V Hepatobiliary Pancreat Dis Int; 2012 Aug; 11(4):412-7. PubMed ID: 22893469 [TBL] [Abstract][Full Text] [Related]
9. Association between praziquantel treatment and cholangiocarcinoma: a hospital-based matched case-control study. Kamsa-Ard S; Luvira V; Pugkhem A; Luvira V; Thinkhamrop B; Suwanrungruang K; Bhudhisawasdi V BMC Cancer; 2015 Oct; 15():776. PubMed ID: 26496745 [TBL] [Abstract][Full Text] [Related]
10. Gene-environment interaction involved in cholangiocarcinoma in the Thai population: polymorphisms of DNA repair genes, smoking and use of alcohol. Songserm N; Promthet S; Pientong C; Ekalaksananan T; Chopjitt P; Wiangnon S BMJ Open; 2014 Oct; 4(10):e005447. PubMed ID: 25335960 [TBL] [Abstract][Full Text] [Related]
11. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Burak K; Angulo P; Pasha TM; Egan K; Petz J; Lindor KD Am J Gastroenterol; 2004 Mar; 99(3):523-6. PubMed ID: 15056096 [TBL] [Abstract][Full Text] [Related]
12. Global identification and characterization of lncRNAs that control inflammation in malignant cholangiocytes. Han BW; Ye H; Wei PP; He B; Han C; Chen ZH; Chen YQ; Wang WT BMC Genomics; 2018 Oct; 19(1):735. PubMed ID: 30305026 [TBL] [Abstract][Full Text] [Related]
13. Trends in Incidence and Factors Affecting Survival of Patients With Cholangiocarcinoma in the United States. Mukkamalla SKR; Naseri HM; Kim BM; Katz SC; Armenio VA J Natl Compr Canc Netw; 2018 Apr; 16(4):370-376. PubMed ID: 29632056 [No Abstract] [Full Text] [Related]
15. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Lewis JT; Talwalkar JA; Rosen CB; Smyrk TC; Abraham SC Am J Surg Pathol; 2010 Jan; 34(1):27-34. PubMed ID: 19898228 [TBL] [Abstract][Full Text] [Related]
16. Cholangiocarcinoma: risk factors and clinical presentation. Gatto M; Alvaro D Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):363-7. PubMed ID: 20496549 [TBL] [Abstract][Full Text] [Related]
17. Statins are associated with a reduced risk of cholangiocarcinoma: a population-based case-control study. Peng YC; Lin CL; Hsu WY; Chang CS; Yeh HZ; Tung CF; Wu YL; Sung FC; Kao CH Br J Clin Pharmacol; 2015 Oct; 80(4):755-61. PubMed ID: 25808421 [TBL] [Abstract][Full Text] [Related]
18. Aspirin use and the risk of cholangiocarcinoma. Choi J; Ghoz HM; Peeraphatdit T; Baichoo E; Addissie BD; Harmsen WS; Therneau TM; Olson JE; Chaiteerakij R; Roberts LR Hepatology; 2016 Sep; 64(3):785-96. PubMed ID: 26940227 [TBL] [Abstract][Full Text] [Related]
19. Biliary dysplasia in primary sclerosing cholangitis harbors cytogenetic abnormalities similar to cholangiocarcinoma. Kerr SE; Barr Fritcher EG; Campion MB; Voss JS; Kipp BR; Halling KC; Lewis JT Hum Pathol; 2014 Sep; 45(9):1797-804. PubMed ID: 25027853 [TBL] [Abstract][Full Text] [Related]
20. MYH rs3219476 and rs3219472 polymorphisms and risk of cholangiocarcinoma. You SH; Wang X; Huang S; Wang M; Ji GZ; Xia JR; Fan ZN Mol Med Rep; 2013 Jan; 7(1):347-51. PubMed ID: 23138270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]